During the corresponding time, Harmony Biosciences Holdings Inc recorded a revenue increase by 30.42 % year on year, sequentially revenue grew by 21.6 %. While revenue at the Harmony Biosciences Holdings Inc 's corporate clients
Harmony Biosciences Holdings Inc's Comment on Sales, Marketing and Customers
For the year ended December 31, 2025, three customers accounted for 100% of the company's gross product revenue: Caremark LLC (38%), Accredo Health Group, Inc. (36%), and PANTHERx Specialty Pharmacy LLC (26%). The company holds a License and Commercialization Agreement with Bioprojet, granting exclusive rights to commercialize a product containing pitolisant (WAKIX) in the United States for indications including narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, Parkinson’s disease, Prader-Willi syndrome (PWS), and diabetes mellitus (DM). The agreement includes milestone payments and tiered royalties based on net sales. Bioprojet retains manufacturing rights within the U.S. and development and commercialization rights outside the U.S. The agreement also covers trademarks, patent rights, and regulatory approvals related to the product.
Harmony Biosciences Holdings Inc’s Comment on Sales, Marketing and Customers
For the year ended December 31, 2025, three customers accounted for 100% of the company's gross product revenue: Caremark LLC (38%), Accredo Health Group, Inc. (36%), and PANTHERx Specialty Pharmacy LLC (26%). The company holds a License and Commercialization Agreement with Bioprojet, granting exclusive rights to commercialize a product containing pitolisant (WAKIX) in the United States for indications including narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, Parkinson’s disease, Prader-Willi syndrome (PWS), and diabetes mellitus (DM). The agreement includes milestone payments and tiered royalties based on net sales. Bioprojet retains manufacturing rights within the U.S. and development and commercialization rights outside the U.S. The agreement also covers trademarks, patent rights, and regulatory approvals related to the product.
Sources:
Harmony Biosciences Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Harmony Biosciences Holdings inc’s corporate clients.
For your research, we’ve provided 9 tables on Harmony Biosciences Holdings inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
182.44 %